ResMed Inc. Q3 2026 Earnings Recap

RMD Q3 2026 May 3, 2026

Get alerts when RMD reports next quarter

Shares fell 3.3% post-earnings, with investor concerns likely centered on the CFO transition rather than the operational results themselves. The retirement of long-tenured CFO Brett Sandercock and the appointment of Aaron Blumer appears to have overshadowed double-digit revenue and EPS growth.

Earnings Per Share Beat

$2.86 vs $2.80 est.

+2.1% surprise

Revenue Beat

1431406000 vs 1419914000 est.

+0.8% surprise

Market Reaction

1-Day -0.74%

5-Day -1.27%

30-Day -0.69%

See RMD alongside your other holdings

Add to your portfolio — free

Key Takeaways

Q3 revenue increased 11% year over year (8% in constant currency).
Non-GAAP EPS grew 21% from the prior year.
Gross margin expanded 290 basis points year over year, and 50 basis points sequentially.
Longstanding CFO Brett Sandercock announced retirement; Aaron Blumer, former Exact Sciences CFO, appointed as successor.
Product innovation continued, with strong adoption of fabric-based masks and expansion of the AirSense 11 platform into new international markets.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit RMD on AllInvestView.

Previous Q2 2026